ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity of immune-related adverse events.

Trial Details

NCT ID
NCT07504796
Phase
PHASE2
Sponsor
NYU Langone Health
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Nivolumab
  • Relatlimab
  • Ipilimumab
  • Signatera genome MRD assay
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Patient must be ≥ 18 years old.
  • Patients must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent from (…
  • Patients must be willing and able to comply with scheduled visits, laboratory tests, and other requirements of the study.
  • Patient must have active advanced melanoma, defined as unresectable stage IIIB-IV by American Joint Committee on Cancer (AJCC) 8th edition. Patient…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →